Research Overview

The Specialty Pharmaceuticals Service assesses commercial health plans’ cost and utilization management strategies for specialty medications across eleven key disease categories. Insights, analyses and recommendations for brand and customer strategies and tactics are provided, as well as ratings of leading manufacturers providing specialty product support.

Eleven key injectable categories are profiled in detail and include:

• Asthma
• Crohn's
• Erythropoiesis-Stimulating Agents (ESAs)
• Hepatitis C
• Hemophilia
• Multiple Sclerosis

• Osteoporosis
• PAH
• Psoriasis
• Rheumatoid Arthritis
• White Blood Cell Stimulants

Who Should Subscribe?

• Marketing, sales, and business strategy executives responsible for specialty medications 
• Payer marketing and corporate account directors and managers
• Pricing, contracting, and reimbursement professionals
• National and regional account managers and directors
• Trade, sales, and marketing teams
• All others doing business in the managed markets, market access, or managed care space

Why Subscribe?

HIRC research benefits manufacturers of specialty products seeking up-to-date knowledge on trends in health plans' management of specialty pharmaceuticals, and employers' involvement and perceptions of specialty benefit management. Developments in the specialty provider market are also reviewed. Research provides in-depth analysis of patient cost-sharing (fixed copays, coinsurance, out-of-pocket limits and deductibles), formulary, utilization management, and pharmaceutical company partners providing value-added services. Includes actionable insights that can assist manufacturers in:

• Anticipate strategic opportunities and threats
• Develop effective product strategies and programs
• Efficiently allocate resources
• Design product launch and pull-through initiatives